President & CEO Bo Rode Hansen leaves Scandion by mutual agreement. CFO Johnny Stilou is appointed interim CEO. The process to identify a new permanent CEO has started.
Read more: https://t.co/vfdHjrEvfU
#Scandion#SCOL#oncology#cancer
It is a pleasure to announce that we have received approvals for the next parts of the CORIST trial, meaning that development of SCO-101 will continue as planned. Patient recruitment for the next part of the trial is expected to commence during the third quarter of 2022.
Scandion Oncology turns five today and is quite a big five-year-old! We have grown to a team of 15 dedicated colleagues who go to work everyday to help develop medicines that can revert cancer’s resistance to treatment and make existing cancer treatments work better and longer.
We are looking forward to participating in the ACCESS CHINA Biotech Forum 2022 conference next week with a presentation by Mads Aaboe Jensen, VP of Business Development and Innovation.
https://t.co/4CuOPRnpiX
#Scandion#SCOL#oncology#cancer
WOW vilka rekryteringar till BoD;
Keld Flintholm Jørgensen - EVP & CBO från Lundbeck
Martine van Vugt - SVP Corporate strategy and Planning från Genmab
Alejandra Mørk - CEO KLIFO A/S
🤩
Det blir mer och mer spännande med utläsning av studierna nu i Q2/Q3
Going forward we will be subject to research and analysis by Edison. With its global audience Edison will strongly support the profiling of Scandion and our mission to revert cancer drug resistance towards the international investment community.
https://t.co/TBczcgKKKU
#Scandion